• 1
    Baily MA, Murray TH (eds). Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore: Johns Hopkins UP, 2009.
  • 2
    Watson M, Mann M, Lloyd-Puryear M, Rinaldo P, Howell R, Group ACoMGNSE. Newborn screening: towrad a uniform screenign panel and system–executive summary. Pediatrics, 2006; 117: S296S307.
  • 3
    Lilley M, Christian S, Hume S et al. Newborn screening for cystic fibrosis in Alberta: two years of experience. Paediatrics and Child Health, 2010; 15: 590594.
  • 4
    Wagener J, Zemanick E, Sontag M. Newborn screening for cystic fibrosis. Current Opinion in Pediatrics, 2012; 24: 329335.
  • 5
    Calonge N, Green N, Rinaldo P et al. Committee report: method for evaluating conditions nominated for population-based screening of newborns and children. Genetics in Medicine, 2010; 12: 153159.
  • 6
    Bailey D. Ethical, legal and social concerns about expanded newborn screening: fragile × syndrome as a prototype for emerging issues. Pediatrics, 2008; 121: e693e704.
  • 7
    Raffle A, Gray J. Screening: Evidence and Practice. Oxford: Oxford UP, 2007.
  • 8
    Grosse S, Boyle C, Kenneson A, Khoury M, Wilfond B. From public health emergency to public health service: the implications of evolving criteria for newborn screening panels. Pediatrics, 2006; 117: 923929.
  • 9
    Moyer V, Calonge N, Teutsch S, Botkin J. Expanding newborn screening: process, policy and priorities. Hasting Center Report, 2008; 38: 3239.
  • 10
    Atkins D, Siegel J, Slutsky J. Making policy when the evidence is in dispute. Health Affairs, 2005; 24: 102113.
  • 11
    Botkin J. Newborn screening for fragile × syndrome: do we care what parents think? Pediatrics, 2011; 127: e1593e1594.
  • 12
    Bombard Y, Miller F, Hayeems R, Avard D, Knoppers B. Reconsidering reproductive benefit: a systematic review of guidelines on preconception, prenatal, and newborn screening. European Journal of Human Genetics, 2010; 18: 751760.
  • 13
    Botkin JR, Clayton EW, Fost N et al. Newborn screening technology: proceed with caution. Pediatrics, 2006; 117: 17931799.
  • 14
    Clayton E. Lessons to be learned from the move toward expanded newborn screening. In: Baily M, Murray T (eds) Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore: Johns Hopkinds UP, 2009: 125135.
  • 15
    Clayton E. Currents in contemporary ethics. State run newborn screening in the genomic era, or how to avoid drowning when drinking from a fire hose. The Journal of Law Medicine and Ethics, 2010; 38: 697700.
  • 16
    Wilson J, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968.
  • 17
    Paul D. Contesting consent: the challenge to compulsory neonatal screening for PKU. Perspectives in Biology and Medicine, 1999; 42: 207219.
  • 18
    Gostin L. Privacy: rethinking health information technology and informed consent. Hasting Center Report 2009; (Suppl): 1517.
  • 19
    Miller F, Hayeems R, Carroll J et al. Consent for newborn screening: the attitudes of health care providers. Public Health Genomics, 2010; 13: 181190.
  • 20
    Moody L, Choudhry K. Parental views on informed consent for expanded newborn screening. Health Expectations 2011; 16: 239250.
  • 21
    Morrison A, Dowler J. Newborn screening for disorders and abnormalities in Canada. Environmental Scan Issue 26. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2011.
  • 22
    Canadian College of Medical Geneticists. CCMG Position Statement: Newborn Screening for Cystic Fibrosis. Ottawa: Canadian College of Medical Geneticists, 2010.
  • 23
    Greenberg C, Jacobs H, Halliday W, Wrogemann K. Three years' experience with neonatal screening for Duchenne/Becker muscular dystrophy: gene analysis, gene expression, and phenotype prediction. American Journal of Medical Genetics, 1991; 39: 6875.
  • 24
    Hildes E, Jacobs H, Cameron A et al. Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy. Journal of Medical Genetics, 1993; 30: 670674.
  • 25
    Eyskens F, Philips E. Newborn screening for Duchenne muscular dystrophy. The experience in the province of Antwerp. Neuromuscular Disorders, 2006; 16: 721.
  • 26
    Cyrus A, Street N, Quary S, Kable J, Kenneson A, Fernhoff P. Clinic-based infant screening for duchenne muscular dystrophy: a feasibility study. PLoS Currents 2012; 4: e4f99c5654147a.
  • 27
    Cirak S, Arechavala-Gomeza V, Guglieri M et al. Exon skipping and dystrophin restoration in Duchenne muscular dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet, 2011; 378: 595605.
  • 28
    Mendell J, Shilling C, Leslie N et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Annals of Neurology, 2012; 71: 304313.
  • 29
    Bodamer O, Hoffmann G, Lindner M. Expanded newborn screening in Europe 2007. Journal of Inherited Metabolic Disease, 2007; 30: 439444.
  • 30
    Atkinson K, Zuckerman B, Sharfstein J, Levin D, Blatt R, Koh H. A public health response to emerging technology: expansion of the Massachusetts newborn screening program. Public Health Reports, 2001; 116: 122131.
  • 31
    Parsons E, Clarke A, Hood K, Lycett E, Bradley D. Newborn screening for Duchenne muscular dystrophy: a psychosocial study. Archives of disease in childhood. Fetal and Neonatal Edition, 2002; 86: F91F95.
  • 32
    de Monestrol I, Burucefors A, Sjoberg B, Hjelte L. Parental support for newborn screening for cystic fibrosis. Acta Paediatrica, 2011; 100: 209215.
  • 33
    Hayes I, Collins J, Sahhar M, Wraith J, Delatycki M. Nwborn screening for mucopolysaccharidoses: opinions of patients and their families. Clinical Genetics, 2007; 71: 446450.
  • 34
    Kerruish N. Parents' experiences of newborn screening for genetic susceptibility to type 1 diabetes. Journal of Medical Ethics, 2011; 37: 348353.
  • 35
    Lipstein E, Nabi E, Perrin J, Luff D, Browning M, Kuhlthau K. Parents' decision-making in newborn screening: opinions, choices and informational needs. Pediatrics, 2010; 126: 696704.
  • 36
    Koopmans J, Ross L. Does familiarity breed acceptance? The influence of policy on physicians' attitudes toward newborn screening programs. Pediatrics, 2006; 117: 14771485.
  • 37
    Hiraki S, Ormond K, Kim K, Ross L. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children. American Journal of Medical Genetics. Part A, 2006; 140A: 23122319.
  • 38
    Schittek H, Koopmans J, Ross L. Pediatricians' attitudes about screening newborns for infectious diseases. Maternal Child Health Journal, 2010; 14: 174183.
  • 39
    Abelson J, Giacomini M, Lehoux P, Gauvin F. Bringing ‘the public’ into health technology assessment and coverage policy decisions: from principles to practice. Health Policy, 2007; 82: 3750.
  • 40
    Schwartz L, Woloshin S, Fowler F, Welch H. Enthusiasm for cancer screening in the United States. JAMA, 2004; 291: 7178.
  • 41
    Welch H. Screening mammography – a long run for a short slide. New England Journal of Medicine, 2010; 363: 12761278.
  • 42
    Bombard Y, Miller F, Hayeems R et al. Citizens' values regarding research with stored samples from newborn screening. Pediatrics, 2012; 129: 239247.
  • 43
    SPSS Inc. PASW Statistics fro Windows [Program]. Version 18.0 Version. Chicago: SPSS Inc., 2009.
  • 44
    Charmaz K. Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis. London, UK: Sage, 2006.
  • 45
    Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Quality and Quantity, 2002; 36: 391409.
  • 46
    Thorne S. Interpretive Description. Walnut Creek, CA: Left Coast Press, 2008.
  • 47
    Sandelowski M. Qualitative analysis: what it is and how to begin. Research in Nursing and Health, 1995; 18: 371375.
  • 48
    Hayeems RZ, Miller FA, Little J et al. Informing parents about expanded newborn screening: influences on health care provider involvement. Pediatrics, 2009; 124: 950958.
  • 49
    Lehoux P, Daudelin G, Demers-Payette O, Boivin A. Fostering deliberations about health innovation: what do we want to know from publics? Social Science and Medicine, 2009; 68: 20022009.
  • 50
    Gollust S, Chandros S, Wilfond B. Limitations of direct-to-consumer advertising for clinical genetic testing. JAMA, 2002; 288: 17621767.
  • 51
    Solomon B, Pineda-Alvarez D, Bear K, Mullikin J, Evans J, Program NCS. Applying genomic analysis to newborn screening. Molecular Syndromology, 2012; 3: 5967.
  • 52
    Kramer B, Brawley O. Cancer screening. Hematology/oncology Clinics of North America, 2000; 14: 831848.
  • 53
    Black W. Overdiagnosis: an underrecognized cause of confusion and harm in cancer screening. Journal of the National Cancer Institute, 2000; 92: 12801282.
  • 54
    Hanley W. Non-PKU mild hyperphenylalaninemia (MHP) – the dilemma. Molecular Genetics and Metabolism, 2011; 104: 2326.
  • 55
    van Spronsen F. Mild hyperphenylalaninemia: to treat or not to treat. Journal of Inherited Metabolic Disease, 2011; 34: 651656.
  • 56
    Notes and Queries in Metab-L. Neonatal screening for MCAD deficiency – how to deal with variant biochemical phenotypes and novel mutations? Molecular Genetics and Metabolism, 2006; 31: 142145.